# OnCo record lorlatinib (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/lorlatinib/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "lorlatinib" ;
  schema:name "Lorlatinib"@en ;
  schema:description "An ALK inhibitor with the longest disease control ever recorded for a targeted lung cancer pill: 60% progression-free at five years."@en ;
  schema:url <https://onco.cc/drugs/lorlatinib/> ;
  schema:dateModified "2026-09-04"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Lorlatinib> ;
  owl:sameAs <http://www.wikidata.org/entity/Q27285820> ;
  schema:citation <https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Lorlatinib>, <https://www.nice.org.uk/guidance/ta628>, <https://www.nice.org.uk/guidance/ta1103> ;
  onco:status "approved" ;
  onco:modality "Small-molecule kinase inhibitor (ALK/ROS1)" ;
  schema:alternateName "Lorbrena" ;
  onco:approval "US 2018: ALK+ NSCLC after prior ALK TKI", "US 2021: First-line ALK+ NSCLC", "England (NICE) 2020: ALK-positive advanced non-small-cell lung cancer progressing after alectinib or ceritinib as the first ALK inhibitor, or after crizotinib and at least one other ALK inhibitor", "England (NICE) 2025: ALK-positive advanced non-small-cell lung cancer not previously treated with an ALK inhibitor" ;
  onco:acceleratedApproval "US 2018-11-02: ALK-positive metastatic NSCLC that has progressed on: • Crizotinib and at least one other ALK inhibitor for metastatic disease; or • Alectinib as the first ALK inhibitor therapy for metastatic disease; or • Ceritinib as the first ALK inhibitor therapy for metastatic disease" ;
  onco:acceleratedApprovalConfirmed "US 2021-03-03: ALK-positive metastatic NSCLC that has progressed on: • Crizotinib and at least one other ALK inhibitor for metastatic disease; or • Alectinib as the first ALK inhibitor therapy for metastatic disease; or • Ceritinib as the first ALK inhibitor therapy for metastatic disease" ;
  onco:related <https://onco.cc/biomarkers/alk-fusion/> ;
  onco:cancers <https://onco.cc/cancers/nsclc/>, <https://onco.cc/cancers/secondary-brain-tumours/>, <https://onco.cc/cancers/neuroblastoma-high-risk/>, <https://onco.cc/cancers/alk-positive-nsclc/>, <https://onco.cc/cancers/lung-cancer/> ;
  onco:technologies <https://onco.cc/technologies/kinase-inhibitors/> ;
  onco:targets <https://onco.cc/targets/alk/> ;
  onco:companies <https://onco.cc/companies/pfizer/> ;
  onco:trials <https://onco.cc/trials/nct05297890/>, <https://onco.cc/trials/crown/> .